Clinical trials: Cardiac Toxicity
HER2-positive Breast Cancer
Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients
Breast cancer can be managed using chemotherapy, endocrine therapy and biological therapy. Treatment is determined and specified according to the characteristics of the tumor including overexpression of the human epidermal growth…
- Trial name
- NCT07233499
- Testing
- Nebivolol 5 mg
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Ain Shams University
Cardiotoxicity, Pulmonary Toxicity
Study on Proton Radiotherapy of Thymic Malignancies
This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e.
- Conditions
- Cardiotoxicity, Pulmonary Toxicity, Thymus Neoplasms
- Trial name
- PROTHYM (NCT04822077)
- Testing
- Proton radiation
- Where
- 3 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Ass. Prof. Jan Nyman
Radiotherapy; Complications, Cardiotoxicity
Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients
The purpose of this study is to evaluate and compare the changes by two modalities: Imaging by Strain by Speckle Tracking and Magnetic Resonance versus soluble markers of cardiac dysfunction as early predictors of cardio-toxicity…
- Conditions
- Radiotherapy; Complications, Cardiotoxicity, Cancer, Lung Cancer
- Trial name
- NCT04896242
- Where
- Chile
- Volunteers
- 47 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Cardiotoxicity
Cardioprotection on Chemotherapy-Induced Cardiotoxicity
The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.
- Trial name
- NCT06853951
- Testing
- ACE Inhibitors, β -Blockers
- Where
- 2 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Cancer;Cardiovascular;Adverse Events, Cancer
Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies
This study will prospectively monitor cancer patients receiving chemotherapy (including molecular targeted therapies) for cardiovascular adverse events using biomarkers and imaging.
- Trial name
- NCT07058454
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma
RElugolix VErsus LeUprolide Cardiac Trial
This clinical trial investigates the impact of prostate cancer treatment, specifically androgen deprivation therapy (ADT), on the heart and coronary vessels among men with localized, non-metastatic prostate cancer undergoing…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- REVELUTION (NCT05320406)
- Testing
- Radiation therapy, Leuprolide, Relugolix
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Emory University
Out-Of-Hospital Cardiac Arrest, Oxygen Toxicity
ORI to Reduce Hyperoxia After Out Hospital Cardiac Arrest
The investigator's research proposal is a randomized controlled study evaluating two different monitoring strategies to titrate FiO2 in order to rapidly and safely achieve optimal SatO2 targets during early ROSC of non-traumatic…
- Trial name
- ORI-ONE (NCT03653325)
- Testing
- ORI measurement, oxygen saturation measurement
- Where
- 2 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Breast Neoplasms, Heart Failure
Cardiotoxicity of Adjuvant Trastuzumab
Trastuzumab (Herceptin®) increases the chances of cure in patients with Her-2 overexpressing early breast cancer. Unfortunately, both the chemotherapy drugs used in this setting (anthracyclines) and trastuzumab are known to cause…
- Trial name
- CATS (NCT00858039)
- Where
- 15 sites in Australia
- Volunteers
- 220 people
- Sponsor
- Royal Prince Alfred Hospital, Sydney, Australia
Coronary Heart Disease
Multi-omics Study of Clinical Endpoints in CHD
This study aimed to explore underlying mechanisms of individual differences in drugs for coronary heart disease treatment and its association with adverse consequences.
- Trial name
- OmiDETCHD (NCT03797339)
- Testing
- risk factors of adverse cardiovascular events, multi-omics target discovery, validation
- Where
- 5 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Guangdong Provincial People's Hospital
Cardiac Toxicity, Malignant Neoplasm
MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum
This trial studies how well magnetic resonance imaging (MRI) works in detecting heart damage in patients with cancer receiving chemotherapy.
- Conditions
- Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
- Trial name
- NCT01719562
- Testing
- Magnetic resonance imaging, Physical Activity, Healthy Living
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Hyperoxia, Cardiac Surgery
Oxygenation Targets in Cardiac Surgery Patients - a Before-and-after Study
During surgery high concentrations of supplementary oxygen are routinely administrated. However, there is increasing evidence of potential harm with liberal oxygen therapy.
- Conditions
- Hyperoxia, Cardiac Surgery, Cardiopulmonary Bypass, Acute Lung Injury
- Trial name
- NCT04133740
- Testing
- Oxygen
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Aalborg University Hospital
Breast Cancer Females
Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. Despite the evidence that aromatase inhibitor therapy is associated with increased risk of cardiovascular events, potentially related to…
- Trial name
- STRIVE-Chronic (NCT06776458)
- Testing
- N/A - Usual Care
- Where
- Canada
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Immune Checkpoint Inhibitors, Cardiotoxicity
Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity
This study is a prospective cohort clinical research that analyzes the changes in CMR parameters before and after immune checkpoint inhibitors (ICIs) therapy in patients with gynecologic malignancies.
- Trial name
- NCT06132984
- Testing
- Cardiac magnetic resonance
- Where
- China
- Volunteers
- 22 people
- Sponsor
- West China Second University Hospital
Breast Cancer, Cardiotoxicity
The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies
The purpose of this study is to determine if exercise preconditioning can mitigate the off target effects of chemotherapy treatment on measures of cardiovascular function, inflammatory responses, and quality of life.
- Conditions
- Breast Cancer, Cardiotoxicity, Cardiovascular Diseases
- Trial name
- NCT05786014
- Testing
- High Intensity Interval Exercise, Moderate Intensity Walking
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Virginia
Cancer, Cardiotoxicity
BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORS
The advent of immunotherapy (immune checkpoint inhibitors [ICI]) has been an extremely important advancement for cancer treatment in recent decades.
- Conditions
- Cancer, Cardiotoxicity, Atherosclerotic Disease
- Trial name
- BIOCAPRI (NCT06597045)
- Testing
- PET/CT with 18-FDG
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- NHS Greater Glasgow and Clyde
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Chemotherapy-induced Cardiotoxicity, Breast Cancer
Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients
This study aims to investigate the possible role of rosuvastatin in protection against cardiotoxicity in HER2 positive breast cancer patients receiving doxorubicin sequential with trastuzumab.
- Trial name
- NCT05338723
- Testing
- Rosuvastatin 20mg
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Cardiac Abnormalities, Chemotherapeutic Toxicity
Effects Of Physical Training On Cardiovascular Capacity In Patients Undergoing Chemotherapy For Cancer
Introduction: Cancer treatment, especially chemotherapy and radiotherapy, can lead to cardiovascular dysfunctions, such as a decrease in left ventricular ejection fraction and electrical dysfunction of the heart, which may…
- Trial name
- Cancer (NCT07640087)
- Testing
- physical training
- Volunteers
- 60 people
- Sponsor
- Federal University of Maranhao
Cardiac Toxicity, Lung Cancer Stage III
COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)
Patients with loco-regional NSCLC planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ECG and cardiac MR…
- Conditions
- Cardiac Toxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
- Trial name
- COLA (NCT05258448)
- Testing
- Chemoradiotherapy
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Odense University Hospital
Anthracycline-induced Cardiotoxicity
Preventing Cardiac Sequelae in Pediatric Cancer Survivors
Cancer therapy can place childhood cancer survivors at increased risk for heart disease which can lead to significant illness or early death.
- Trial name
- PCS2 (NCT01805778)
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,128 people
- Sponsor
- The Hospital for Sick Children